William J Gradishar

  • 11605 Citations
1988 …2022
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

My clinical domain is breast cancer management. My clinical research interest focuses on the development of novel therapies for the treatment of breast cancer. Clinical trials focusing on precision medicine for defining the right therapy, for the right patient at the right time is our goal. To that end, molecular interogation of breast tumors are leading to novel trial design that will hopefully translate into better outcomes for our patients. In conjuction with the developmental therapeutics program, novel agents are being incorporated into clinical trials for patients with both early and late stage disease.

Certifications and Licenses

Internal Medicine
Medical Oncology

Training Experience

1986Residency, Michael Reese Medical Center
1990Fellowship, University of Chicago Hospitals

Education/Academic qualification

MD, University of Illinois - Chicago

… → 1982

Keywords

  • Breast Cancer
  • Chemotherapy
  • Clinical Research
  • Drug Discovery
  • Drugs (clinical pharmacology)
  • Genomic Medicine/Personalized Medicine
  • Medical Education

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

Breast Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
docetaxel Medicine & Life Sciences
Tamoxifen Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Aromatase Inhibitors Medicine & Life Sciences
Adjuvant Chemotherapy Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 1999 2022

Patient Care
Neoplasms
Patient Care Planning
Patient-Centered Care
Patient Rights

Research Output 1988 2019

A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapy

Zhou, Z., Feng, Z., Hu, D., Yang, P., Gur, M., Bahar, I., Cristofanilli, M., Gradishar, W. J., Xie, X. Q. & Wan, Y., Jun 1 2019, In : EBioMedicine. 44, p. 98-111 14 p.

Research output: Contribution to journalArticle

Open Access
Triple Negative Breast Neoplasms
Methylation
Tumors
Molecules
Genes

Breast cancer, version 3.2018 featured updates to the NCCN guidelines

Goetz, M. P., Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., Farrar, W. B., Giordano, S. H., Goldstein, L. J., Isakoff, S. J., Lyons, J., Kelly Marcom, P., Mayer, I. A., Moran, M. S., Mortimer, J., O’Regan, R. M. & 13 othersPatel, S. A., Pierce, L. J., Reed, E. C., Rugo, H. S., Sitapati, A., Smith, K. L., Smith, M. L., Soliman, H., Telli, M. L., Ward, J. H., Young, J. S., Shead, D. A. & Kumar, R., Feb 1 2019, In : JNCCN Journal of the National Comprehensive Cancer Network. 17, 2, p. 118-126 9 p.

Research output: Contribution to journalArticle

Open Access
Adjuvant Chemotherapy
Hormones
Guidelines
Breast Neoplasms
Therapeutics
Colorectal Neoplasms
Neoplasms
Research
Diagnostic Services
Patient Rights

NCCN Guidelines Updates: Breast Cancer

Telli, M. L., Gradishar, W. J. & Ward, J. H., May 1 2019, In : Journal of the National Comprehensive Cancer Network : JNCCN. 17, 55, p. 552-555 4 p.

Research output: Contribution to journalArticle

Guidelines
Triple Negative Breast Neoplasms
Breast Neoplasms
Precision Medicine
Axilla

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone

Sestak, I., Martín, M., Dubsky, P., Kronenwett, R., Rojo, F., Cuzick, J., Filipits, M., Ruiz, A., Gradishar, W. J., Soliman, H., Schwartzberg, L., Buus, R., Hlauschek, D., Rodríguez-Lescure, A. & Gnant, M., Jan 1 2019, In : Breast Cancer Research and Treatment.

Research output: Contribution to journalArticle

Open Access
Breast Neoplasms
Drug Therapy
Therapeutics
Adjuvant Chemotherapy
Proportional Hazards Models